MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
WEB3 days ago · What is the news? Pfizer announced the withdrawal of voxelotor (Oxbryta®) from national and global markets on September 25, 2024. Clinical research was also stopped.
FDA is alerting patients and health care professionals about the ...
WEB4 days ago · In postmarketing clinical trials of Oxbryta, Pfizer reported a higher rate of vaso-occlusive crisis (severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago · Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient...
Pfizer decision to withdrawal sickle cell drug leaves patients ... - STAT
WEB5 days ago · Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for...
Pfizer withdraws sickle-cell disease treatment | Reuters
WEB5 days ago · Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N) said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB5 days ago · Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths. The...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB6 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB5 days ago · Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago.
FDA alerts patients about Pfizer's Oxbryta withdrawal
WEB4 days ago · The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB4 days ago · Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
- Some results have been removed